Lexaria Bioscience Corp (LEXX) Stock Price, Quote & News

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH i...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 765 6424

Website: lexariabioscience.com

Address:

740 McCurdy Road, Suite 100, Kelowna, Canada

DW65 Dec. 5 at 12:56 PM

$LEXX if you want to review. https://www.clinicaltrials.gov/study/NCT06648031

0 · Reply

wa7ermelon Dec. 5 at 12:45 PM

$LEXX

0 · Reply

wa7ermelon Dec. 5 at 12:44 PM

$LEXX $LEXX $NVO

0 · Reply

Titosrbija Dec. 5 at 12:22 PM

$LEXX my man. It is forbidden to be negative or realistic on this board.

1 · Reply

Turbofueled Dec. 5 at 12:13 PM

$LEXX $LEXX The time has come!! put the results out lets see this go crazy!🌋

0 · Reply

Makingmillions192 Dec. 5 at 12:08 PM

$LEXX Another short seller looking scared lol

0 · Reply

IldijanaMM Dec. 5 at 11:48 AM

$LEXX Cash position doesn’t look promising

1 · Reply

Boston7452 Dec. 5 at 12:12 AM

$LEXX Looks likely to be a blood thinner/anticlotting agent actually. Thats what Dr Gibson specializes in. Company might be AstraZeneca.

1 · Reply

wa7ermelon Dec. 5 at 12:05 AM

$LEXX

0 · Reply

Boston7452 Dec. 4 at 11:31 PM

$LEXX Looking at Lex's scientific board, formed after the MTA, with an MD & PHD related to vascular health, I'd say the MTA has to do with blood pressure or something related to the heart. https://lexariabioscience.com/2024/12/18/lexaria-forms-new-scientific-advisory-board/

3 · Reply

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Oct 9, 2025, 9:20 AM EDT - 2 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Sep 29, 2025, 4:30 PM EDT - 2 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 2 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2025, 11:20 AM EDT - 2 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Aug 27, 2025, 9:20 AM EDT - 3 months ago

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 14, 2025, 9:20 AM EDT - 4 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 6, 2025, 9:20 AM EDT - 4 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Jul 28, 2025, 9:25 AM EDT - 4 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 4 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 23, 2025, 9:25 AM EDT - 4 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jun 23, 2025, 9:15 AM EDT - 5 months ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 11, 2025, 9:05 AM EDT - 6 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 5, 2025, 9:20 AM EDT - 6 months ago

Lexaria Attending BIO International Convention

May 12, 2025, 9:00 AM EDT - 7 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Apr 28, 2025, 4:15 PM EDT - 7 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 8 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 23, 2025, 9:10 AM EDT - 8 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 3, 2025, 9:10 AM EDT - 8 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 2, 2025, 9:05 AM EDT - 8 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Mar 18, 2025, 9:15 AM EDT - 9 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 9 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Feb 27, 2025, 8:00 AM EST - 10 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 24, 2025, 8:00 AM EST - 10 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 20, 2025, 8:00 AM EST - 10 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 11, 2025, 8:00 AM EST - 10 months ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 6, 2025, 9:40 AM EST - 10 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Jan 30, 2025, 9:15 AM EST - 11 months ago

Lexaria Releases Annual Letter from the CEO

Jan 15, 2025, 9:20 AM EST - 11 months ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 14, 2025, 9:10 AM EST - 11 months ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board

Dec 17, 2024, 9:10 AM EST - 1 year ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 9, 2024, 9:10 AM EST - 1 year ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Nov 26, 2024, 9:20 AM EST - 1 year ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 25, 2024, 9:00 AM EST - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 20, 2024, 9:05 AM EST - 1 year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 14, 2024, 9:10 AM EST - 1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 13, 2024, 9:20 AM EST - 1 year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 7, 2024, 9:15 AM EST - 1 year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Oct 24, 2024, 9:10 AM EDT - 1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 1 year ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 1 year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 8, 2024, 9:20 AM EDT - 1 year ago

Lexaria Updates Current GLP-1 Market

Oct 1, 2024, 9:25 AM EDT - 1 year ago

Lexaria Appoints Michael Shankman as Chief Financial Officer

Sep 27, 2024, 9:20 AM EDT - 1 year ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Sep 5, 2024, 10:00 AM EDT - 1 year ago

Lexaria Releases Strategic Letter from the Outgoing CEO

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Lexaria Welcomes Industry Veteran as New CEO

DW65 Dec. 5 at 12:56 PM

$LEXX if you want to review. https://www.clinicaltrials.gov/study/NCT06648031

0 · Reply

wa7ermelon Dec. 5 at 12:45 PM

$LEXX

0 · Reply

wa7ermelon Dec. 5 at 12:44 PM

$LEXX $LEXX $NVO

0 · Reply

Titosrbija Dec. 5 at 12:22 PM

$LEXX my man. It is forbidden to be negative or realistic on this board.

1 · Reply

Turbofueled Dec. 5 at 12:13 PM

$LEXX $LEXX The time has come!! put the results out lets see this go crazy!🌋

0 · Reply

Makingmillions192 Dec. 5 at 12:08 PM

$LEXX Another short seller looking scared lol

0 · Reply

IldijanaMM Dec. 5 at 11:48 AM

$LEXX Cash position doesn’t look promising

1 · Reply

Boston7452 Dec. 5 at 12:12 AM

$LEXX Looks likely to be a blood thinner/anticlotting agent actually. Thats what Dr Gibson specializes in. Company might be AstraZeneca.

1 · Reply

wa7ermelon Dec. 5 at 12:05 AM

$LEXX

0 · Reply

Boston7452 Dec. 4 at 11:31 PM

3 · Reply

Boston7452 Dec. 4 at 11:22 PM

$LEXX Point #1: The MTA was extended so PharmaCo can review the data, yes. However that does not mean the MTA is for use of Dehydra with GLP for PharmaCo. Using AI generative information to counter my concern seems disingenuous. This is further reinforced by how AI references the CEO's letter in point 2. AI is claiming that because Lex is focusing on GLP, and that the MTA is also mentioned, the MTA must be for that. However, this is not indicated in the CEO's letter. CEO simply mentions both facts without associating them. Point #3 I do not even understand how that AI came up with that as no evidence indicates that the MTA was for PharmaCo to test Lex IP with GLP. That evidence doesnt exist and if it did you wouldnt be using AI to try to counter my concern that the MTA doesnt have to do with GLP1.

3 · Reply

wa7ermelon Dec. 4 at 11:14 PM

$LEXX $LEXX $NVO Imagine if Lexaria announce a licensing deal which covers both GLP-1 and Alzheimers applications. Now that would be mega.

0 · Reply

wa7ermelon Dec. 4 at 11:05 PM

$LEXX Boston thinks its for erectile dysfunction 🫠

0 · Reply

Boston7452 Dec. 4 at 10:28 PM

$LEXX and the pumpers here want you to associate Lex's MTA with GLP. Yet the PR's mentioned here do not indicate the MTA has anything to do with GLP. Why? The highlighted portion talks about the MTA. Then, IN ADDITION, Lex talks about how the PharmaCo wants to see the results. Most people will assume the two are related but if Lex has not officially said so but seems to want you to believe they are associated, then the MTA is likely for something far less headline driving than GLP. Be careful.

1 · Reply

Boston7452 Dec. 4 at 10:07 PM

$LEXX Anyone know if Lexx's MTA has anything to do with GLP? The original press release doesnt specify which drug and the most recent one does not either. It only indicates that the company wants to see Lex's Australian study results.

1 · Reply

Boston7452 Dec. 4 at 9:34 PM

$LEXX There is no reason to copy and paste what ive said i dont deny being interested in Lex. Im just skeptical of the companies history of chasing market trends and I am not sure this is as valuable as people claim it could be. Thus im watching and will swing it.

1 · Reply

wa7ermelon Dec. 4 at 9:23 PM

$LEXX look whose after an entry 😂😂😂

1 · Reply

Makingmillions192 Dec. 4 at 8:36 PM

$LEXX Cmon baby you know you want $1.30 😉

0 · Reply

Shubeedoo Dec. 4 at 8:19 PM

$LEXX Or maybe I'm just smoking some Hopium

1 · Reply

Shubeedoo Dec. 4 at 8:18 PM

$LEXX Be nice to see a little action on the close and a $1.20+ start tomorrow

0 · Reply

PennyConnection1 Dec. 4 at 7:58 PM

$LEXX Boston is right y’all, he’s being realistic and not a pumper…

1 · Reply

wa7ermelon Dec. 4 at 7:44 PM

if $RANI can do 750% move on a$10M upfront licensing deal, what can $LEXX do with a $50-100m upfront deal with Novo or Eli Lilly?

0 · Reply

Market Cap	24.67M
Revenue (ttm)	710,000.00
Net Income (ttm)	-11.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,676.06%
Debt to Equity Ratio	0.00

Volume	212,800
Avg Vol	661,964
Day's Range	N/A - N/A
Shares Out	22.23M
Stochastic %K	58%
Beta	0.63
Analysts	Strong Sell
Price Target	$5.33